**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | EANO | **Project Code** | PB4LSS080 |
| **Virtual Project Manager** | Choose an item. | **Clinical Program Manager** |  |
| **Compliance** | ---------- | **Editor** | Heather Tomlinson |

**Project Type Email Blast Included?**

Webcast  Yes

Downloadable Slides  No

CD/DVD Subject Line: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Email Only

Podcast

Other:\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Content Available by:\_\_\_\_\_\_\_\_

**Audience** **CME?**

US Yes

Ex-US  No

EU

Global (Both Ex-US and US)

Other:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ **Registration**

Regonline Link:\_\_\_\_\_\_\_\_\_\_\_\_

**Slides Included**  CRM Event ID(s): \_\_\_\_\_\_\_\_\_\_\_\_

Yes

No **Additional Components**

Cases with Voting

Polls

Video Segmentation

Slides Available by:\_\_\_\_\_\_\_\_\_  Table of Contents

Other:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Slides Synched? (if included in Webcast)**

Yes

No

**Mobile App Title:** EANO Glioblastoma

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

1. **[Meeting-Associated Webcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Advances and Challenges in the Management of Glioblastoma**

**ACTIVITY FEATURES**

[Icon] Interactive Presentation

[Icon] Downloadable Slides

[Icon] CME-Certified

[Insert screen shot]

**ACTIVITY OVERVIEW**

This CME-certified Webcast contains **video and downloadable slides** from the symposium *Advances and Challenges in the Management of Glioblastoma,* a prIME Oncology educational activity in conjunction with the 11th European Association of NeuroOncology Conference that was held on 9 October 2014, in Turin, Italy.

**TOPICS**

Current therapeutic options in glioblastoma: Progress or status quo?

*James Perry, MD*

Expanding role of advanced imaging in the management of glioblastoma

*Alexander Radbruch, MD, JD*

Molecular biomarkers beyond *MGMT* promoter hypermethylation: Hope or hype?

*Wolfgang Wick, MD*

Back to the future: Exploring novel research directions

*Michael Weller, MD*

**FACULTY**

**Co-Chairs**

Michael Weller, MD

University Hospital of Zürich

Zürich, Switzerland

Wolfgang Wick, MD

University of Heidelberg and German Cancer Research Center

Heidelberg, Germany

**Faculty**

James Perry, MD

Sunnybrook Health Sciences Center

University of Toronto

Toronto, Ontario, Canada

Alexander Radbruch, MD, JD

University of Heidelberg

Heidelberg, Germany

**TARGET AUDIENCE**

This educational activity is specifically designed for medical oncologists, neurologists, and other healthcare professionals involved in the treatment of patients with glioblastoma.

**LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

• Discuss the standard and emerging therapeutic options for managing glioblastoma

• Identify the imaging modalities that can help to more precisely and accurately follow tumor progression and treatment response

• Evaluate patient biomarkers to inform prognosis

**CONTINUING MEDICAL EDUCATION**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of XX *AMA PRA Category 1 Credits™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**METHOD OF PARTICIPATION**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

**DISCLOSURES**

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Weller has disclosed that he has received consulting fees from Celldex, Isarna, Magforce, Merck Serono, Pfizer, Roche, and Teva. Dr Weller disclosed that he performed contracted research for Acceleron, Bayer, Isarna, MSD, Merck Serono, Phytopharmaceutical Sciences, and Roche. He has received fees for Non-CME Services from Isarna, Merck Serono, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wick has disclosed that he has received consulting fees from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Perry has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Radbruch has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

• Bojana Pajk, MD, MSc (medical content reviewer/planner) – no relevant financial relationships

• Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**PROVIDER**

This activity is provided by prIME Oncology.

**SUPPORTER**

This educational activity is supported by a grant from F. Hoffmann-La Roche Ltd.

**ACTIVITY DATE**

Release Date

Expiration Date

1. **Web Activity Page Titles**

Landing Page Title: Advances and Challenges in the Management of Glioblastoma  
Activity Page Title:

Current therapeutic options in glioblastoma: Progress or status quo?

Expanding role of advanced imaging in the management of glioblastoma

Molecular biomarkers beyond MGMT promoter hypermethylation: Hope or hype?

Back to the future: Exploring novel research directions

1. **Meta Description**An educational meeting on imaging, biomarkers, and treatment for glioblastoma chaired by Wolfgang Wick and Michael Weller held at EANO in Turin, Italy

**Key Words and Key Phrases**

Glioblastoma

EANO

Neurooncology

Brain cancer

Glioblastoma imaging

Glioblastoma biomarkers

MGMT

Bevacizumab

Avastin

Pseudo-progression

Glioblastoma pseudo-progression

Perfusion MRI

Targeted therapy for glioblastoma

Glioblastoma therapy

Glioblastoma treatment

IDH-1/2 mutation

PRoB-GBM

GLARIUS trial